The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Oligonucleotide therapies for disorders of the nervous system
Open accessAbstract
Oligonucleotide therapies are currently experiencing a resurgence driven by advances in backbone chemistry and discoveries of novel therapeutic pathways that can be uniquely and efficiently modulated by the oligonucleotide drugs. A quarter of a century has passed since oligonucleotides were first applied in living mammalian brain to modulate gene expression. Despite challenges in delivery to the brain, multiple oligonucleotide-based compounds are now being developed for treatment of human brain disorders by direct delivery inside the blood brain barrier (BBB). Notably, the first new central nervous system (CNS)-targeted oligonucleotide-based drug (nusinersen/Spinraza) was approved by US Food and Drug Administration (FDA) in late 2016 and several other compounds are in advanced clinical trials. Human testing of brain-targeted oligonucleotides has highlighted unusual pharmacokinetic and pharmacodynamic properties of these compounds, including complex active uptake mechanisms, low systemic exposure, extremely long half-lives, accumulation and gradual release from subcellular depots. Further work on oligonucleotide uptake, development of formulations for delivery across the BBB and relevant disease biology studies are required for further optimization of the oligonucleotide drug development process for brain applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it prevents the transfer of most of small-molecule drugs and macromolecules (e.g., peptides, gene drugs, and protein drugs) into the brain (1–6).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The treatment of central nervous system (CNS) diseases, such as neurodegenerative disorders, brain tumors, brain infections, and stroke, is severely constrained by the blood-brain barrier (BBB) because it prevents the transfer of most of small-molecule drugs and macromolecules (e.g., peptides, gene drugs, and protein drugs) into the brain (1–6).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some ASOs were clinically approved for certain neuromuscular diseases and are currently in trials for other conditions.184,185”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [184]
The cited source says what the claim attributes to it.
In the citing paper
“The U.S. Food and Drug Administration approved the first CNS-related oligonucleotide-based drug, Nusinersen, for treating spinal muscular atrophy caused by a survival motor neuron (SMN) protein deficiency.”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [184]
The cited source says what the claim attributes to it.
In the citing paper
“Nusinersen is designed to modify the splicing of the SMN2 (Survival of motor neuron 2, centromeric) gene, increasing the production of functional SMN protein.184,186,187”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme
Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N., & Altman, S. (1983) · Cell · doi:10.1016/0092-8674(83)90117-4 · Cited by 2,684
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Antisense Transcription in the Mammalian Transcriptome
Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura, M., Nishida, H., Yap, C.-S., Suzuki, M., Kawai, J., et al. (2005) · Science · doi:10.1126/science.1112009 · Cited by 1,699
Self-citationCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
Catalanotto, C., Cogoni, C., & Zardo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101712 · Cited by 1,238
Genome-wide Identification of Polycomb-Associated RNAs by RIP-seq
Zhao, J. C., Ohsumi, T. K., Kung, J. T., Ogawa, Y., Grau, D., Sarma, K., Song, J. J., Kingston, R. E., Borowsky, M. L., & Lee, J. T. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.011 · Cited by 1,008
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J., Albuquerque, R., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 939
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 904
Flagged first, then by citations
Research works printed but not linked: 3
- Cook, P.D. & Guinosso, C.J. 2′-O-modified nucleosides and phosphoramidites. US patent no. 5,914,396 (1995).
- Wahlestedt, C., Yee, F., Yoo, H., Koob, G.F. & Heilig, M. in Molecular Neurobiology, Proceedings of the second NIMH Conference (eds. Zalcman, S., Scheller, R. & Tsien, R.) (1992).
- DeVos, S.L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, 374 (2017). · DOI · Paper page
Cited by
Sorted by citations
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Long non-coding RNAs: From disease code to drug role
Chen, Y., Li, Z., Chen, X., & Zhang, S. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.001 · Cited by 515
Long Noncoding RNA in Cancer: Wiring Signaling Circuitry
Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488
Han, Z., Chen, C., Christiansen, A., Ji, S., Lin, Q., Anumonwo, C., Liu, C., Leiser, S. C., Meena, Aznarez, I., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6100 · Cited by 341
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 338
EMT : Present and future in clinical oncology
Santamarı́a, P. G., Moreno‐Bueno, G., Portillo, F., & Cano, A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12091 · Cited by 263
Ma, F., Yang, L., Sun, Z., Chen, J., Rui, X., Glass, Z., & Xu, Q. (2020) · Science Advances · doi:10.1126/sciadv.abb4429 · Cited by 218
Liu, B., Hu, F., Zhang, J., Wang, C., & Li, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903417 · Cited by 174
RNA therapy: Are we using the right molecules?
Yu, A., Jian, C., Yu, A. H., & Tu, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 167
Cheng, Y., Sun, C., Liu, R., Yang, J., Dai, J., Zhai, T., Lou, X., & Xia, F. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901527 · Cited by 161
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Moumné, L., Marie, A.-C., & Crouvezier, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020260 · Cited by 169
Chemical modifications of nucleic acid drugs and their delivery systems for gene‐based therapy
Chen, C., Yang, Z., & Tang, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21479 · Cited by 164
Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer
Diamantopoulos, M. A., Tsiakanikas, P., & Scorilas, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.10 · Cited by 139
Antisense oligonucleotides in neurological disorders
Wurster, C. D., & Ludolph, A. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418776932 · Cited by 133
Amplifying gene expression with RNA-targeted therapeutics
Khorkova, O., Stahl, J., Joji, A., Volmar, C., & Wahlestedt, C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00704-7 · Cited by 136
Self-citationAntisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
Fusco, D. D., Dinallo, V., Marafini, I., Figliuzzi, M. M., Romano, B., & Monteleone, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00305 · Cited by 126
Simchovitz, A., Hanan, M., Niederhoffer, N., Madrer, N., Yayon, N., Bennett, E. R., Greenberg, D., Kadener, S., & Soreq, H. (2019) · The FASEB Journal · doi:10.1096/fj.201900830r · Cited by 119
A perspective on oligonucleotide therapy: Approaches to patient customization
Thakur, S., Sinhari, A., Jain, P., & Jadhav, H. R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006304 · Cited by 114
Wang, B., Tang, M., Yuan, Z., Li, Z., Hu, B., Bai, X., Chu, J., Xu, X., & Zhang, X.-Q. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.026 · Cited by 112
Aptamer-Based Targeted Protein Degradation
Liu, Y., Qian, X., Ran, C., Li, L., Fu, T., Su, D., Xie, S., & Tan, W. (2023) · ACS Nano · doi:10.1021/acsnano.2c10379 · Cited by 110
Migliorati, J. M., Liu, S., Liu, A., Gogate, A., Nair, S., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000417 · Cited by 110
Samaridou, E., Walgrave, H., Salta, E., Álvarez, D. M., Castro-López, V., Loza, M. I., & Alonso, M. J. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119657 · Cited by 100
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 95
Luo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 85
Durán, R. C., Wei, H., Kim, D. H., & Wu, J. Q. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12541 · Cited by 76
Chen, L., Watson, C. A., Morsch, M., Cole, N. J., Chung, R. S., Saunders, D. N., Yerbury, J. J., & Vine, K. L. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00476 · Cited by 68
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
Opportunities and challenges for microRNA-targeting therapeutics for epilepsy
Morris, G., O’Brien, D., & Henshall, D. C. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.007 · Cited by 67
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome
Shao, Y., Sztainberg, Y., Wang, Q., Bajikar, S. S., Trostle, A. J., Wan, Y., Jafar‐Nejad, P., Rigo, F., Liu, Z., Tang, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7785 · Cited by 61
Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
Li, Q. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.4.273 · Cited by 67
Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain
Padmakumar, S., Jones, G., Pawar, G. N., Khorkova, O., Hsiao, J. H., Kim, J., Amiji, M. M., & Bleier, B. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.027 · Cited by 62
Self-citationAdvances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 68
Molecular mechanisms of psychiatric diseases
Blokhin, I. O., Khorkova, O., Saveanu, R. V., & Wahlestedt, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105136 · Cited by 64
Self-citationStrauss, K. A., Carson, V. J., Brigatti, K. W., Young, M., Robinson, D. L., Hendrickson, C. L., Fox, M. D., Reed, R. M., Puffenberger, E. G., Mackenzie, W. G., et al. (2018) · Journal of Pediatric Orthopaedics · doi:10.1097/bpo.0000000000001247 · Cited by 61
Li, D., Mastaglia, F. L., Fletcher, S., & Wilton, S. D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21718 · Cited by 59
Sun, Y., Zhao, Y., Zhao, X., Lee, R. J., Teng, L., & Zhou, C. (2017) · Molecules · doi:10.3390/molecules22101724 · Cited by 56
Rodrigues, M., & Yokota, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8651-4_2 · Cited by 56
Papachristodoulou, A., Silginer, M., Weller, M., Schneider, H., Hasenbach, K., Janicot, M., & Roth, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3024 · Cited by 52
Oligonucleotide-mediated tRNA sequestration enables one-pot sense codon reassignment in vitro
Cui, Z., Wu, Y., Mureev, S., & Alexandrov, K. A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky365 · Cited by 47
Krichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 48
Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
Kim, Y. J., Sivetz, N., Layne, J., Voss, D. M., Yang, L., Zhang, Q., & Krainer, A. R. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114858118 · Cited by 48
Long noncoding RNA loss in immune suppression in cancer
Hu, Q., Egranov, S. D., Lin, C., & Yang, L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107591 · Cited by 46
Reschke, C. R., Silva, L. F. A., Vangoor, V. R., Rosso, M., David, B., Cavanagh, B. L., Connolly, N. M. C., Brennan, G. P., Sanz-Rodriguez, A., Mooney, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.021 · Cited by 42
Cheng, Y., Sun, C., Liu, R., Yang, J., Dai, J., Zhai, T., Lou, X., & Xia, F. (2019) · Angewandte Chemie · doi:10.1002/ange.201901527 · Cited by 43
Clinical Pharmacokinetics of Approved RNA Therapeutics
Jo, S. J., Chae, S. U., Lee, C. B., & Bae, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010746 · Cited by 41
Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching
Dawicki-McKenna, J. M., Felix, A. J., Waxman, E. A., Cheng, C., Amado, D. A., Ranum, P. T., Bogush, A., Dungan, L. V., Maguire, J. A., Gagne, A. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38273-3 · Cited by 41
Tripathi, S., Shree, B., Mohapatra, S., Swati, S., Basu, A., & Sharma, V. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02268-8 · Cited by 43
Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer
Dong, B., Qiu, Z., & Wu, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.596239 · Cited by 40
Bortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Cyclodextrins based delivery systems for macro biomolecules
Liu, J., Ding, X., Fu, Y., Xiang, C., Yuan, Y., Zhang, Y., & Yu, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113105 · Cited by 39
The dysregulation of miRNAs in epilepsy and their regulatory role in inflammation and apoptosis
Xie, G., Chen, H., He, C., Hu, S., Xiao, X., & Luo, Q. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01220-y · Cited by 35
LncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimer’s Disease
Liu, Y., Chen, X., Che, Y., Li, H., Zhang, Z., Peng, W., & Yang, J. (2022) · Aging and Disease · doi:10.14336/ad.2021.1119 · Cited by 35
Focused shockwave induced blood-brain barrier opening and transfection
Kung, Y., Chiang, L., Hsiao, M., Sun, M., Hsu, Y.-H., Huang, A. P., Liao, W., Liu, H.-L., Inserra, C., & Chen, W. (2018) · Scientific Reports · doi:10.1038/s41598-018-20672-y · Cited by 33
Thadke, S. A., Perera, J. D. R., Hridya, V. M., Bhatt, K. S., Shaikh, A. Y., Hsieh, W., Chen, M., Gayathri, C., Gil, R. R., Rule, G. S., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00062 · Cited by 33
Dong, H., Han, L., Wang, J., Xie, J., Gao, Y., Xie, F., & Jia, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.004 · Cited by 32
Nanocarriers for Delivery of Oligonucleotides to the CNS
Male, D. K., & Gromnicova, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020760 · Cited by 32
Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies
Padmakumar, S., D’souza, A. A., Parayath, N. N., Bleier, B. S., & Amiji, M. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.018 · Cited by 30
Nucleic acid-based artificial nanocarriers for gene therapy
Zhu, L., Luo, J. S., & Ren, K. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01179d · Cited by 31
Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier
Amulya, E., Sikder, A., Vambhurkar, G. B., Shah, S., Khatri, D. K., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.031 · Cited by 30
CLIP6-PNA-Peptide Conjugates: Non-Endosomal Delivery of Splice Switching Oligonucleotides
Soudah, T., Mogilevsky, M., Karni, R., & Yavin, E. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00638 · Cited by 29
Nash, L. A., McFall, E. R., Perozzo, A. M., Turner, M., Poulin, K. L., Repentigny, Y. D., Burns, J. K., McMillan, H. J., Warman‐Chardon, J., Burger, D. E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14313-z · Cited by 30
Coding and long non-coding gene expression changes in the CNS traumatic injuries
Wu, X., Wei, H., & Wu, J. Q. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04092-2 · Cited by 28
Fahoum, F., & Eyal, S. (2023) · Epilepsia · doi:10.1111/epi.17625 · Cited by 27
Advanced gene therapy system for the treatment of solid tumour: A review
Ma, Y., Liao, J., Cheng, H., Yang, Q., & Yang, H. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101138 · Cited by 28
Current Strategies and Novel Drug Approaches for Alzheimer Disease
Ghai, R., Nagarajan, K., Arora, M., Grover, P., Ali, N., & Kapoor, G. T. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200717091513 · Cited by 29
Liu, B., Hu, F., Zhang, J., Wang, C., & Li, L. (2019) · Angewandte Chemie · doi:10.1002/ange.201903417 · Cited by 28
Wu, X., Xia, P., Yang, L., Lü, C., & Lu, Z. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.03.008 · Cited by 26
Chen, C., Wang, Z., Zhang, J., Fan, X., Xu, L., & Tang, X. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00204 · Cited by 26
Preclinical Safety Assessment of Therapeutic Oligonucleotides
Andersson, P. U. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_25 · Cited by 28
Boujnouni, N. E., van der Bent, M. L., Willemse, M. P., Hoen, P. A. C. ’., Brock, R. E., & Wansink, D. G. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.010 · Cited by 24
Padmakumar, S., Jones, G., Khorkova, O., Hsiao, J. H., Kim, J., Bleier, B. S., & Amiji, M. M. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120989 · Cited by 23
Self-citationEpigenetics and noncoding RNA: Recent developments and future therapeutic opportunities
Henshall, D. C. (2019) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.06.002 · Cited by 23
Nucleic acid-based therapeutics for the treatment of central nervous system disorders
McCartan, R., Khorkova, O., Volmar, C., & Wahlestedt, C. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1250276 · Cited by 22
Self-citationAlkylation enhances biocompatibility and siRNA delivery efficiency of cationic curdlan nanoparticles
Erdene-Ochir, T., Ganbold, T., Zandan, J., Han, S., Borjihan, G., & Baigude, H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.048 · Cited by 22
Ji, W., Zhou, H., Liang, W., Zhang, W., Gong, B., Yin, T., Chu, J., Zhuang, J., Zhang, J., Luo, Y., et al. (2024) · Small · doi:10.1002/smll.202308574 · Cited by 22
Guo, L., Mann, J. R., Mauna, J. C., Copley, K. E., Wang, H. H., Rubien, J. D., Bergmann, C. A., Carey, J., Merjane, J., Ngo, M., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2025.12.009 · Cited by 24
Ursu, A., Wang, K. W., Bush, J. A., Choudhary, S., Chen, J. L., Baisden, J. T., Zhang, Y., Gendron, T. F., Petrucelli, L., Yildirim, I., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00049 · Cited by 20
Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1
Liu, J., Guo, Z., Yan, X., Yang, Y., & Huang, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.755392 · Cited by 23
Forrest, M. P., Santos, M. D., Piguel, N. H., Wang, Y., Hawkins, N. A., Bagchi, V. A., Dionisio, L. E., Yoon, S., Simkin, D., Martin‐de‐Saavedra, M. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36087-x · Cited by 22
Long non-coding RNA-targeting therapeutics: discovery and development update
Khorkova, O., Stahl, J., Joji, A., Volmar, C., Zeier, Z. R., & Wahlestedt, C. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2236552 · Cited by 21
Self-citationWada, F., Yamamoto, T., Ueda, T., Sawamura, M., Wada, S., Harada‐Shiba, M., & Obika, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0698 · Cited by 23
Nucleic Acid–Based Therapeutics in Orphan Neurological Disorders: Recent Developments
Khorkova, O., Hsiao, J. H., & Wahlestedt, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.643681 · Cited by 22
Self-citationSymmetrization of the backbone of nucleic acids: a molecular dynamics study
Pant, P., Pathak, A., & Jayaram, B. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1585292 · Cited by 21
Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery
Volpini, L., Monaco, F., Santarelli, L., Neužil, J., & Tomasetti, M. (2023) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2023.100005 · Cited by 21
Non-protein biologic therapeutics
Sharfstein, S. T. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.12.014 · Cited by 20
Wu, Q., Zhang, Y., An, H., Sun, W., Wang, R., Liu, M., & Zhang, K. (2021) · Oncogene · doi:10.1038/s41388-021-01849-8 · Cited by 20
Peptide-based nanomaterials for gene therapy
Zhang, W., Chen, Q., Wu, F., Dai, J., Ding, D., Wu, J., Lou, X., & Xia, F. (2020) · Nanoscale Advances · doi:10.1039/d0na00899k · Cited by 20
Natural antisense transcripts as drug targets
Khorkova, O., Stahl, J., Joji, A., Volmar, C., Zeier, Z. R., & Wahlestedt, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.978375 · Cited by 22
Self-citationZhao, W., Li, M., Wang, S., Li, Z., Li, H., & Li, S. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12850 · Cited by 18
Geraci, J., Bhargava, R., Qorri, B., Leonchyk, P., Cook, D. J., Cook, M., Sie, F., & Pani, L. (2024) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2023.1199736 · Cited by 19
RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges
Yuan, W., Shi, X., & Lee, L. T. O. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102195 · Cited by 22
Influenza virus segment 5 (+)RNA - secondary structure and new targets for antiviral strategies
Soszynska-Jozwiak, M., Michalak, P., Moss, W. N., Kierzek, R., Piasecka, J., & Kierzek, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-15317-5 · Cited by 19
Liu, X., Liu, W., Chen, Q., Liu, J., Yang, C., Zhang, G., Zhang, S., Guo, W., Li, J., Zhao, G., et al. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23310 · Cited by 18
Enhancing Neuronal Cell Uptake of Therapeutic Nucleic Acids with Tetrahedral DNA Nanostructures
Martins, A. S. G., Reis, S., Benson, E., Domingues, M. M., Cortinhas, J., Silva, J. A. V., Santos, S. D., Santos, N. C., Pêgo, A. P., & Moreno, P. M. D. (2024) · Small · doi:10.1002/smll.202309140 · Cited by 17
Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma
Desgraves, J., Valdez, M. J. M., Chandar, J. S., Gurses, M. E., Henderson, L. J., Castro, J. R., Seetheram, D., Ivan, M. E., Komotar, R. J., & Shah, A. H. (2024) · Cancers · doi:10.3390/cancers16101944 · Cited by 17
The recent advancements in protein nanoparticles for immunotherapy
Xu, M., Wei, S., Duan, L., Ji, Y., Han, X., Sun, Q., & Weng, L. (2024) · Nanoscale · doi:10.1039/d4nr00537f · Cited by 19
Ai, R., Mao, L., Jin, X., Campos‐Marques, C., Zhang, S., Pan, J., Lagartos-Donate, M. J., Cao, S., Barros‐Santos, B., Nóbrega‐Martins, R., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady9811 · Cited by 20
Bajikar, S. S., Sztainberg, Y., Trostle, A. J., Tirumala, H. P., Wan, Y., Harrop, C. L., Bengtsson, J. D., Carvalho, C. M. B., Pehlivan, D., Suter, B., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae135 · Cited by 16
Pant, P., Pathak, A., & Jayaram, B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2061594 · Cited by 16
Metadata
- Authors
- Khorkova, O., & Wahlestedt, C.
- Affiliations
- OPKO Health (United States) (US)
- University of Miami (US)
- Corresponding author
- Wahlestedt, Claes
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 249-263
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC6043900
- OpenAlex
- W2593574576
- Cited by
- 179
- References
- 118
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 17 · 2020: 23 · 2019: 20 · 2018: 20 · 2017: 10
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (R01AA023781)
- National Institute on Aging (RC2AG036596)
- National Institute of Mental Health (R01MH083733)
- National Institute on Drug Abuse (R01DA025983, R21DA035592)
- National Institute of Neurological Disorders and Stroke (R01NS063974, P50NS071674, R01NS081208)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- oligonucleotide therapeutics, central nervous system disorders, blood-brain barrier, nusinersen, antisense oligonucleotides, oligonucleotide delivery, pharmacokinetics, pharmacodynamics, oligonucleotide uptake, drug formulation, neurodegenerative diseases
- MeSH terms
- Animals, Brain Diseases, Humans, Oligonucleotides, Genetic Therapy, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
